Novavax Reports the Pediatric Expansion for P-III Clinical Trial of NVX-CoV2373 Against COVID-19

 Novavax Reports the Pediatric Expansion for P-III Clinical Trial of NVX-CoV2373 Against COVID-19

Shots:

  • The company has reported the expansion of P-III PREVENT-19 pivotal trial to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 vs PBO in ~3,000 adolescents aged 12-17yrs. against COVID 19 across 75 sites in the US
  • Patients will receive two doses of either NVX-CoV2373 or PBO given 21 days apart and participants will be monitored for safety for up to 2 yrs. following the final dose
  • In a recent UK trial, Novavax’s vaccine was 96.4% effective against the original strain, 86.3% effective against the B.1.1.7/501Y.V1 variant and 89.7% overall

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Novavax

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post